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a  b  s  t  r  a  c  t
Dengue  is  the  most  important  arthropod-borne  viral  disease  in  humans,  with  an  estimated  3.6  billion
people  at  risk  for infection  and more  than  200  million  infections  per year.  Identiﬁcation  of  the  cellular
receptors  for dengue  virus  (DV),  the  causative  agent  of  dengue,  is  important  toward  understanding  the
pathogenesis  of  the  disease.  Heparan  sulfate  (HS)  has  been  characterized  as a DV  receptor  in multiple
model  systems,  however  the  physiological  relevance  of  these  ﬁndings  has been  questioned  by  observa-
tions  that  ﬂaviviruses,  including  DV,  can  undergo  cell culture  adaptation  changes  resulting  in increased
binding  to  HS.  It thus remains  unclear  whether  HS  is  utilized  by  clinical,  non-cell  culture-adapted  strains
of  DV.  To address  this  question,  herein  we  describe  a set  of methodologies  using  recombinant  subviral
particles  (RSPs)  to determine  the  utilization  of HS by  clinical  strains  of  DV  serotype  1 (DV1). RSPs of
clinically  isolated  strains  with  low  cell  culture  passage  histories  were  used  to study  HS  interaction.  Bio-
chemically  characterized  RSPs  showed  dose-dependent  binding  to  immobilized  heparin,  which  could  be
competed  by  heparin  and  HS but  not  structurally  related  glycosaminoglycans  chondroitin  sulfate  A and
hyaluronic  acid.  The  relevance  of heparin  and HS  biochemical  interactions  was  demonstrated  by  compe-
tition  of  RSP  and  DV  binding  to  cells  with  soluble  heparin  and  HS.  Our  results  demonstrate  that  clinical
strains  of DV1  can  speciﬁcally  interact  with  heparin  and  HS.  Together,  these  data  support  the possibility
that  HS on cell  surfaces  is  utilized  in  the  DV-human  infection  process.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.. Introduction
Dengue is a mosquito-borne disease of increasing threat to pub-
ic health in many tropical and subtropical regions around the world
nd shows a growing geographical footprint. Dengue causes sig-
iﬁcant morbidity and mortality worldwide, with approximately
30 million infections and 21,000 deaths annually, along with
ubstantial economic costs and burden to healthcare systems
Gubler, 2012). Infection with DV results in a wide spectrum
f clinical manifestations, ranging from asymptomatic presenta-
ion, to ﬂu-like febrile disease termed dengue fever (DF), and
otentially to more severe and life-threatening forms termed
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Open access under CC BY license.dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS) (Halstead, 2007; Harris et al., 2000). With no approved spe-
ciﬁc treatment or vaccine, dengue is a signiﬁcant and growing
global public health issue (Farrar et al., 2007; Miller, 2010; Simmons
et al., 2012).
DV is composed of four closely related serotypes, termed 1–4,
and is a member of the Flavivirus genus, along with other important
human pathogens including tick-borne encephalitis virus (TBEV),
West Nile virus (WNV), and Japanese encephalitis virus (JEV). Struc-
turally, DV is an enveloped positive single-stranded RNA virus.
The 10.7 kb RNA genome of DV is comprised of three structural
genes, which encode for capsid (C), premembrane (prM), and enve-
lope glycoprotein (gpE), as well as seven non-structural genes.
The mature virus particle structure is approximately 50 nm in
diameter, with the outer surface composed of 90 gpE homod-
imers arranged with icosahedral symmetry (Kuhn et al., 2002).
During the natural ﬂavivirus infection process, subviral particles
(SPs) in addition to virions, are generated (Corver et al., 2000;
Russell et al., 1980). SPs are characterized as non-infectious par-
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pE surface proteins on a lipid bilayer but are devoid of capsid
nd an RNA genome (Allison et al., 2003). SPs can be produced
ecombinantly by the co-expression of prM and gpE genes in mam-
alian cells (Holmes et al., 2005; Hsieh et al., 2008; Liu et al.,
010; Schalich et al., 1996). RSPs have similar envelope protein pre-
entation, hemagglutination and fusion activity to infectious virus
articles (Corver et al., 2000; Schalich et al., 1996). As a result,
SPs have been exploited as an alternative to infectious DV for
iverse applications, including vaccine development, delivery sys-
ems, and antigens for diagnostics as reviewed elsewhere (Shang
t al., 2012).
Like many other enveloped viruses, DV infects host cells
rst by recognizing and binding receptor(s) on cell surfaces,
owever no clear consensus of the receptor identities for DV
as emerged. Multiple putative receptors found on different
ell types have been proposed, including DC-SIGN on primary
uman monocyte-derived dendritic cells and Langerhan cells;
annose receptor on macrophages; Fc  receptor on various
mmune cells; phosphatidylserine-receptor TIM and TAM pro-
eins (Cabrera Hernandez and Smith, 2005; Hidari and Suzuki,
011); and HS on multiple cell lines, including human hepatoma
ell (Huh7), Vero cells, CHO cells and BHK-21 cells (Chen et al.,
997; Germi et al., 2002; Hilgard and Stockert, 2000; Kato et al.,
010; Lin et al., 2002), as well as other cell types (Dalrymple
nd Mackow, 2011; Okamoto et al., 2011; Thaisomboonsuk et al.,
005; Thepparit et al., 2004). HS is a member of the glycosamino-
lycan (GAG) family of glycans and is extensively found on the
urface of mammalian cells. Structurally, it is composed of a
epeating disaccharide unit of glucuronic acid linked to N-acetyl-
lucosamine (Sasisekharan et al., 2006). HS chains have been
hown to serve as attachment factors for a variety of microor-
anisms and viruses, including ﬂaviviruses (Zhu et al., 2011). In
ultiple studies, HS has been shown to play a role in the DV infec-
ion process (Hilgard and Stockert, 2000; Martinez-Barragan and
el Angel, 2001; Thepparit et al., 2004), suggesting that HS may
ndeed serve as a receptor or co-receptor for DV infection of host
ells.
Other studies investigating the role of HS in DV infection have
emonstrated that DV, when propagated under certain conditions
n vitro, can undergo adaptive changes resulting in increased afﬁn-
ty for and utilization of HS for cell infection (Anez et al., 2009;
ee et al., 2006b; Prestwood et al., 2008). Indeed, similar studies
ith other ﬂaviviruses, including TBEV and JEV, have also shown
he potential of these viruses to undergo genetic changes upon cell
ulture propagation which also confer an increased HS binding phe-
otype (Lee and Lobigs, 2002; Mandl et al., 2001). These results call
nto question whether naturally circulating DV strains utilize HS as
n attachment factor.
To address this question, we generated RSPs which encode
rM–gpE sequences of four DV1 strains, two of which repre-
ent low-passage clinical isolates and two of strains extensively
assaged in cell culture. Puriﬁed RSPs were biochemically and bio-
hysically characterized for their integrity and similarity to dengue
irions. Characterized RSPs of clinical DV isolates, in addition to
dapted strains, were shown to bind immobilized heparin, and
his interaction could be speciﬁcally competed with heparin and
S but not chondroitin sulfate and hyaluronic acid. HS interac-
ions were further interrogated using a cell-based assay, in which
SPs of clinical and adapted strains were shown to bind Vero
ells in a manner which could be competed for by heparin and
S. Similarly, Vero cell binding of a DV1 strain with an exten-
ive passage history could also be competed for by heparin and
S, supporting that the ﬁndings with RSPs reﬂect infectious virus
echanisms. Collectively, these results support the notion that DV
tilizes HS on cell surfaces as an attachment factor during the infec-
ion process.rch 176 (2013) 69– 77
2. Methods
2.1. Cell lines and viruses
Suspension human embryonic kidney 293 Freestyle (Freestyle
293) cells were purchased from Life Technologies and maintained
in Freestyle 293 medium (Life Technologies). Vero and C6/36 cells
were obtained from ATCC and cultured with DMEM/F12 supple-
mented with 10% FBS and EMEM supplemented with glutamine
and 10% FBS, respectively (Life Technologies). Spodoptera frugiperda
(Sf9) cells were purchased from ATCC, adapted to serum-free sus-
pension culture, and maintained with BD BaculoGold medium (BD
Bioscience). DV serotype 1 strain TH-Sman was purchased from
ATCC and was grown in C6/36 cells.
2.2. gpE expression
Full length prM and 80% gpE (i.e., C-terminus 20% truncated)
from DV1 strain FGA/NA d1d (Despres et al., 1998) was codon opti-
mized and synthesized with a C-terminus 6X histidine tag (DNA
2.0). PrM-gpE was cloned using XmaI and BglII into PAcGP67a
plasmid (BD Bioscience). Baculovirus of prM–gpE was generated
following manufacturer’s instructions (BD Bioscience). Suspension
Sf9 cells were infected with prM–gpE baculovirus, and conditioned
medium was  harvested 48 h post-infection and puriﬁed by FPLC
using a HisTrap HP column (GE healthcare). The identity of gpE
was conﬁrmed by western blot and ELISA analyses probing with
conformational-sensitive 4G2 and 1A1D2 antibodies, as described
below.
2.3. RSP production
Codon optimized prM–gpE DNA sequences from all selected
strains (Supplemental Table 1) were synthesized (DNA 2.0) and
cloned into pcDNA 3.3 vectors (Life Technologies). Freestyle 293
cells were transiently transfected with puriﬁed plasmids using
25 kD linear polyethylenimine (Polyscience, Inc.,). After 5 days, cul-
ture supernatants containing RSPs were clariﬁed at 3000 × g for
10 min  and subsequently ﬁltered through a 0.2 m ﬁlter. RSPs were
then pelleted by ultracentrifugation at 28,000 rpm for 4 h using
rotor 32 Ti (Beckman Coulter). Pelleted RSPs were resuspended in
PBS and subsequently puriﬁed by sucrose gradient (20–60%) ultra-
centrifugation. Sucrose solution was made in 20 mM HEPES pH
7.4 with 6 mL  of each layer and an increment of 10% of sucrose.
Ultracentrifugation was carried out at 28,000 rpm for 2.45 h. 1.5-
mL fractions were harvested and assessed for the presence of gpE
by western blot with 4G2, as described below. Fractions contain-
ing RSPs were further processed by dialysis and then concentrated
using 100KD MWCO  Amicon Ultra-15 centrifugal ﬁlter unit (Milli-
pore). All steps were performed at 4 ◦C.
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.virusres.2013.04.017.
2.4. Anti-dengue monoclonal antibody (mAb) production
Flavivirus cross-reactive mouse mAb  4G2 was produced by
HB-112 hybridoma cells, which were purchased and maintained
as described by ATCC. mAb  1A1D-2 (Lok et al., 2008) was produced
by Freestyle 293 transient transfection. Brieﬂy, DNA  sequences of
1A1D-2 heavy chain and light chain variable regions (PDB acces-
sion 2R69) were synthesized (DNA 2.0) and cloned into pcDNA 3.3
plasmids harboring human heavy chain and light chain constant
region sequences, respectively. Both plasmids were transfected
into Freestyle 293 cells, as described above. Both antibodies were
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.5. Western blotting analysis
RSP samples were separated by 4–12% NuPAGE bis–Tris
DS-PAGE gel and transferred to nitrocellulose membrane (Life
echnologies). Membrane was subsequently probed with 4G2
nti-ﬂavivirus mAb  (Kuwahara and Konishi, 2010) followed by goat
nti-mouse IgG with conjugated HRP (Santa Cruz Biotechnology).
he membrane was developed with ECL Advanced Western Blot
etection Kit (GE Healthcare) and visualized by gel documentation.
he data were analyzed by Alpha View program (ProteinSimple).
For quantitative western blot analyses, ﬁve serial dilutions of
uriﬁed gpE protein were included in each blot for generation of a
tandard curve. RSP samples were diluted appropriately to ﬁt in the
inear range of the standard curve. All samples were loaded into gels
ith equal volumes, and run as described above. To generate the
tandard curve, the intensity of gpE monomer was plotted against
ts corresponding concentration. The standard curve was  plotted,
nd concentration was calculated using Alpha view software (Pro-
einSimple) (Supplemental Fig. 1).
Supplementary material related to this article found, in the
nline version, at http://dx.doi.org/10.1016/j.virusres.2013.04.017.
.6. Transmission electron microscopy (TEM)
RSP samples were ﬁrst puriﬁed by immunoafﬁnity chromatog-
aphy (IAC) using 4G2 mAb  coupled to CNBr-resin. The puriﬁed RSPs
ere buffer exchanged to PBS and stored at 4 ◦C for subsequent
tudies. RSPs were adsorbed onto FORMVAR carbon ﬁlm coated
opper grid (Electron Microscopy Sciences), washed drop-wise
ith 1 mL  of PBS, then stained with 2% uranyl acetate in water. The
tained grid was observed by transmission electron microscope at
agniﬁcation of 150,000×.
.7. MALDI mass spectrometry
Mass spectra were acquired on an Applied Biosystems 4800 Plus
ALDI TOF/TOF Analyzer, equipped with a 355 nm Nd:YAG laser.
 mg/mL  solution of sinapinic acid in 1:1, acetonitrile/water with
.1% TFA was used as matrix. On a standard 384-well stainless steel
ALDI sample plate, 0.5 L of IAC-puriﬁed RSPs samples and 0.5 L
f matrix solution was spotted and mixed in one well. Mass spectra
ere acquired under positive ion linear mode.
.8. Heparin-binding ELISA
Heparin was conjugated to BSA using sodium acetate buffer pH
.2 with the reductive amination agent sodium cyanoborohydride
s described elsewhere (Hoffman et al., 1983). Heparin–BSA
onjugate was puriﬁed from unconjugated BSA and heparin by
SKgel G3000SWxl (Tosoh Bioscience) size exclusion HPLC using
BS pH 6.5 as running buffer. Heparin–BSA (or BSA as a negative
ontrol) was coated overnight at 4 ◦C onto Maxisorb (Nunc) 96-well
lates. The wells were blocked with 1% skim milk and then RSP
erial dilutions in PBS were added. After 2 h, wells were washed
nd bound RSPs were detected with 1A1D-2 antibody followed
y horseradish peroxidase conjugated rabbit anti-human IgG
Jackson immuno-research laboratory). TMB  microwell peroxidase
ubstrate (KPL Inc.) was used as a substrate for spectrophotomet-
ic detection. 100 L of 1 N sulfuric acid was added to stop the
eaction and absorbance at 450 nm was measured. For soluble
AG competition studies, the same procedure was used with
ne modiﬁcation. Before applying RSPs to the plate containing
dsorbed heparin–BSA, RSPs at 200 g of gpE equivalence/mL were
rst preincubated for 2 h with equal volume of serially dilutedrch 176 (2013) 69– 77 71
GAGs in PBS. The mixtures were then applied to the heparin–BSA
adsorbed plates and processed as described above.
2.9. RSP-Vero cell inhibition assay
Vero cells were seeded into 96-well plates and incubated
overnight to allow attachment. RSPs at 6 M equivalence of gpE in
serum-free DMEM/F12 medium were mixed 1:1 (v:v) with heparin
or HS in serum-free medium and incubated for 2 h. The RSP–glycan
mixtures were then incubated for 4 h at 37 ◦C with seeded Vero
cells. Unbound RSPs were removed by gently washing twice with
200 L of serum-free medium. The cells were then ﬁxed by addition
of 3.7% formaldehyde for 20 min  at room temperature. After wash-
ing twice with PBS, the cells were permeabilized using 0.1% Triton
X-100 in PBS for 30 min. The permeabilized cells were washed
3 times with PBS then bound RSPs were detected with 100 L
of 1 g/mL of 1A1D2 followed by 100 L of 1:10,000 of rabbit
anti-human IgG HRP conjugated (Jackson Immuno-Research Lab-
oratory) in PBST. Bound RSPs were colorimetrically visualized as
described previously in ELISA assay.
2.10. DV1 Vero cell inhibition assay
DV1 strain TH-Sman (50 focus-forming units) was  incubated
with heparin or HS in 100 L of serum-free DMEM for 2 h and sub-
sequently incubated with Vero cell monolayers in 24-well plates
for 4 h at 37 ◦C to allow virus adsorption. The unbound virus
was gently washed with 1 mL  of serum-free DMEM,  and an over-
lay of 2% serum-supplemented DMEM with 1% Aquacide (Merck
Biosciences) was applied to wells. After 5 days, the overlay was
removed and cells were ﬁxed with buffered formalin. Cells were
permeabilized by 0.1% Triton X-100 in PBS and virus foci detected
by use of 1A1D-2 antibody.
3. Results
3.1. Strain selection and RSP expression
Multiple lines of evidence have indicated that DV utilizes HS as
an attachment factor during in vitro infection of cells (Chen et al.,
1997; Germi et al., 2002; Hilgard and Stockert, 2000; Kato et al.,
2010; Lin et al., 2002; Martinez-Barragan and del Angel, 2001;
Thepparit et al., 2004; Watterson et al., 2012). However, passaging
of DV in vitro, under certain conditions, has been shown to augment
DV infection sensitivity to HS and heparin (Anez et al., 2009; Lee
et al., 2006b; Prestwood et al., 2008). It remains unclear whether
natural circulating strains of DV, which have not undergone exten-
sive in vitro passaging, also utilize HS as a receptor. To examine
whether clinical DV isolates utilize HS, we ﬁrst constructed RSPs
representing four strains of DV1. Two  strains, ThD1-0102 and
BR-DF02 (designated L-ThD1 and L-BR, respectively), are of clin-
ical, low-passage isolates, and two  strains, 45AZ5 PDK-0/PDK-27
and TH-Sman (designated H-45AZ5 and H-TH, respectively) are
characterized with more extensive cell culture passage histories
(Supplemental Table 1). L-ThD1 was derived directly from an
infected human sample without any passaging (Tang et al., 2010)
and L-BR has been passaged 3 times in C6/36 cell line (Carvalho
et al., 2010). Strain H-45AZ5, which has been shown to display a
small plaque phenotype, a sign of increased heparin interaction, has
undergone signiﬁcant passaging as part of development as a vac-
cine candidate (Puri et al., 1997). Strain H-TH was passaged multiple
times in suckling mice followed by passaging in C6/36 cells (Shiu
et al., 1992).
DNA sequences encoding prM and gpE gene sequences from the
four selected strains were synthesized and cloned into mammalian
expression plasmids. RSPs were expressed by transient transfection
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Fig. 1. Biochemical and biophysical characterization of RSPs. (A) Sucrose gradient analysis of RSPs. Resuspended pellet from ultracentrifugation of transfected HEK 293 cell
supernatant was overlaid onto 20–60% sucrose gradient. After ultracentrifugation for 2.5 h, 1.5 mL  fractions were harvested from top to bottom and analyzed by western
blot.  The amount of gpE in each fraction was normalized by the fraction with maximum intensity of its strain. (B) RSP structure by TEM. IAC-puriﬁed RSP was adsorbed onto a
carbon  coated grid then stained with 2% uranyl acetate under magniﬁcation of 180,000×. Embedded bar represents 40 nm in length. (C) MALDI-MS of RSPs. IAC-puriﬁed RSP
was  analyzed using MALDI TOF/TOF analyzer equipped with 355 nm Nd:YAG laser using 5 mg/mL  solution of sinapinic acid in 1:1, acetonitrile/water with 0.1% TFA as matrix.
A  representative mass spectrum is displayed. (D) Western blot of RSP expression. The expression of RSP of H-45AZ5 (lane 1), L-ThD1 (lane 2), L-BR (lane 3), and H-TH (lane


















intibody. (E) Quantiﬁcation of RSP expression levels. The amount of gpE monomer f
Ab.  Puriﬁed recombinant gpE was included in the western blot as a standard prot
f suspension HEK-293 cells with prM–gpE expression vectors and
upernatants were puriﬁed by sucrose gradient ultracentrifugation,
s described in Section 2.
.2. RSP characterization
Western blot of 1.5 mL  fractions collected from sucrose gradient
ltracentrifugation of RSPs (see Section 2) revealed the majority
f gpE sedimented in fractions that correlated to 20–30% sucrose
olution (Fig. 1A). Interestingly, two peaks of gpE after sucrose
radient ultracentrifugation were found for all strains, indicating
he presence of two distinct populations, a ﬁnding consistent with
llison et al., which demonstrated two different sizes of ﬂavivirus
SPs (Allison et al., 2003). To further investigate the particulate
ature of the RSPs, samples were treated with Triton-X 100, a
urfactant which disrupts lipid bilayer-containing particles, prior
o sucrose gradient ultracentrifugation. Analysis of the fractions
evealed gpE to be present in the top fraction (data not shown),
ndicating production of RSPs in intact particulate form (Schalichpernatant of transfected HEK 293 cells was quantiﬁed by western blot using 4G2
 generate a standard curve. Error bars represent standard deviation.
et al., 1996; Wang et al., 2009). To further assess the structural
features of expressed RSPs, TEM of RSP samples was performed,
which revealed the majority of RSPs to be round with the diameter
of approximately 30 nm and a minority population with 50 nm
diameter, ﬁndings consistent with previous studies (Allison et al.,
2003; Liu et al., 2010; Schalich et al., 1996) (Fig. 1B and Supple-
mental Fig. 2). Results from ultracentrifugation and TEM analyses
collectively demonstrate expression of intact RSPs with correct
size.
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.virusres.2013.04.017.
To characterize protein constituents of RSPs, MALDI-MS of RSP
samples was performed. Resultant spectra revealed three major
peaks corresponding to molecular weights of approximately 8 kD
(data not shown), 20 kD and 57 kD (Fig. 1C), which match closely
to the theoretical molecular weights of M (8 kD), prM (20 kD) and
glycosylated gpE (57 kD) (Allison et al., 2003; Schalich et al., 1996;
Wang et al., 2009). To conﬁrm results obtained by MS,  RSP samples
were analyzed by western blot using the gpE-speciﬁc antibody 4G2.

































































cig. 2. RSP interaction with heparin by ELISA. Maxisorp plates coated with puriﬁed 
SPs  were used to show a dose response interaction. Error bars represent standard
onditioned medium containing expressed RSP was  centrifuged to
ellet intact RSPs, separating RSP from soluble gpE and degraded
articles. Western blot of resuspended pellets demonstrated
pE present at approximately 55 kD and 110 kD, indicating both
onomeric and dimeric forms of gpE (Fig. 1D). The presence of
imeric gpE further supports the expression of gpE in particulate
orm, as gpE is present as a homodimer in mature virus and subviral
articles (Kuhn et al., 2002). Additionally, the diffuse banding of
pE in western blot is consistent with the protein being glycosy-
ated (Mondotte et al., 2007). Results obtained by TEM, MS  and
estern blot were similar across RSPs of the four different strains
ith no signiﬁcant differences. Overall, these results demonstrate
SPs are composed of the correct protein composition.
To determine RSP expression of the different strains, quan-
iﬁcation of RSPs was performed by western blot using puriﬁed
ecombinant gpE as a standard. RSP expression levels for the dif-
erent strains ranged from 0.6 to 6 g of gpE monomer equivalence
er mL  of culture supernatant (Fig. 1E). While expression lev-
ls across multiple transfections varied little for individual RSP
trains, expression between strains of RSP varied as much as
0-fold, suggesting the particular sequences may  have a direct role
n the expression and assembly efﬁciency of RSPs. Collectively,
nalyses by ultracentrifugation, TEM, MALDI-MS, and western
lot all support that expressed RSPs are of the correct size and
omposition.
.3. RSP binding to HS by ELISA
Characterized RSPs of both clinical isolates and cell
ulture-adapted strains were then tested for their ability to
ecognize HS, ﬁrst by a heparin ELISA method, which has been
reviously utilized for interrogating HS–virus interactions in a
umber of studies (Kato et al., 2010; Marks et al., 2001; Pattnaik
t al., 2007; Watterson et al., 2012). Importantly, the assay incor-
orates heparin in an immobilized format, and thus heparin is
resented in a similar manner as on the surface of cells. In a
ose-dependent manner, RSPs were tested for their ability to
ind heparin conjugated to BSA which was passively immobilized
n microtiter plates. All RSPs showed signiﬁcant binding above
ackground at concentrations as low as 148 nM gpE equivalence
n a dose-dependent manner (Fig. 2). The binding patterns varied
mong different virus strains, with L-ThD1 and L-BR strains
low-passage strains) reaching saturation at 1.3 M gpE whereas
he high-passage strains did not reach saturation at the highest
oncentration of 12 M gpE. These results indicate that both
linical and highly passaged strains bind heparin, and surprisingly,n–BSA were used to assess heparin binding of DV RSPs. Various concentrations of
tion.
highly passaged strains H-45AZ5 and H-TH showed lower binding
efﬁciency than clinical strain RSPs.
3.4. Effect of soluble GAGs on RSPs binding to heparin on
heparin-ELISA
While many studies characterizing DV–glycan interactions did
not test both heparin and HS, some studies found that DV prefer-
entially interacts with heparin with little or no binding to HS  (Chen
et al., 1997; Marks et al., 2001). Heparin is a highly sulfated form
of HS and its expression is restricted to mast cells in connective
tissues, whereas HS is ubiquitously found on most mammalian cell
surfaces. We  therefore sought to characterize the speciﬁcity of RSP
binding to GAGs more broadly, including HS.
Heparin binding ELISA experiments were carried out with the
modiﬁcation that RSPs were ﬁrst incubated with different GAGs
in solution, allowing them to compete for RSP–heparin interac-
tion (see Section 2). Heparin, HS, chondroitin sulfate A (CSA), and
hyaluronic acid (HA) were included as soluble GAGs in competi-
tion studies. As anticipated, soluble heparin was able to effectively
compete binding of all RSP strains to immobilized heparin, a ﬁnd-
ing that also supports the interaction being speciﬁc to heparin
and not involving BSA (Table 1). Heparin was the most potent
competitor followed by HS. Conversely, CSA and HA showed no
competition despite using glycan concentrations up to 1 mg/mL.
Additionally, H-45AZ5 and H-TH required lower concentrations
of heparin and HS (∼10-fold) than the low-passage strain RSPs
to reach their half maximal inhibition concentration, indicating a
potential greater afﬁnity of L-BR and L-ThD1 to heparin than that
of H-45AZ5 and H-TH strains. The results indicate that RSPs of both
low- and high-passage strains bind speciﬁcally to heparin and HS,
but not HA and CSA. Interestingly, these results also suggest that
electrostatic charge from sulfate groups (absent in HA) and carbo-
hydrate backbone (i.e., heparin and HS have different disaccharide
backbone than CS) may  be important structural factors contributing
to binding speciﬁcity, a ﬁnding consistent with other HS-binding
viruses (Chen et al., 1997; Hilgard and Stockert, 2000; Kato et al.,
2010; Marks et al., 2001; Watterson et al., 2012).
3.5. Effect of soluble heparin/HS on RSP-Vero cells binding
To further investigate the involvement of HS as an attachment
factor for DV, binding assays were performed with cells, which bet-
ter capture the natural diversity and presentation of glycans that
DV would encounter compared to ELISA-based methods. To deter-
mine whether RSP binding to cells would capture key elements of
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Table 1
RSP binding speciﬁcity probed by heparin ELISA with various competing GAGs.
RSP strain IC50 (g/mL)
Heparin Heparan sulfate Chondroitin sulfate A Hyaluronic acid













aL-ThD1-0102 0.66 66.00 
L-BR-DF02 0.54 47.70 
H-TH-Sman 0.01 0.15
nfectious DV binding to cells, initial cell-binding control experi-
ents were performed with both RSP and infectious DV of the same
train, TH-Sman. Heparin and HS were able to similarly inhibit
oth RSP and DV binding to cells (Fig. 3). These results support the
otion that RSPs have similar gpE presentation as infectious virus
o interact with receptors on target cells, a ﬁnding consistent with
revious studies (Corver et al., 2000; Schalich et al., 1996).
To test all strains, RSPs were incubated with medium con-











































ig. 3. GAG inhibition of strain TH-Sman of infectious DV and RSP. (A) Infectious DV TH-Sma
as  then applied to Vero cells in 24 well–well plates and incubated for 5 days. Foci were v
s  a percentage relative to PBS as a negative control. (B) Puriﬁed TH-Sman RSP was  incub
fter  2 h incubation, samples were added to Vero cell monolayers seeded in 96-well plate
nd  bound RSP was  detected by anti-gpE antibody. Error bars represent standard deviatio>10,000 >10,000
>10,000 >10,000
>10,000 >10,000
the mixtures were applied to Vero cell monolayers. Both soluble
heparin and HS at 0.1 mg/mL  signiﬁcantly inhibited RSPs-Vero cell
binding for all four strains. For RSP of H-TH, for example, inhibition
was as low as 47% for heparin and 44% for HS compared to no
treatment control group (Fig. 4). The inhibitory potency between
heparin and HS for each strain in this assay is not signiﬁcantly
different. These results indicate both clinical and high-passage
strain RSPs bind HS on cells and are consistent with previous ELISA
results demonstrating heparin and HS binding of all strains.
eparin Heparan sulfate
eparin Heparan sulfate
n (50 ffu/well) was  incubated with heparin, HS or PBS for 2 h at 37 ◦C. The mixture
isualized after ﬁxing by probing with anti-gpE antibody. Infected cells are reported
ated with DMEM/F12 medium containing heparin, HS or PBS as a negative control.
s and incubated for 4 h at 37 ◦C to allow RSP binding to cells. Cells were then ﬁxed
n.

































































fig. 4. GAG inhibition of RSP binding to Vero cells. Puriﬁed RSPs were incubated wit
fter  2 h incubation, samples were added to Vero cell monolayers seeded in 96-we
nd  bound RSPs were detected by anti-gpE antibody. Error bars represent standard
. Discussion
This study was motivated by the question of whether HS is
sed as an attachment factor during infection of clinical strains
f DV. Multiple previous studies have shown adaptation of DV by
aining of a positive charge substitution in gpE after continuously
assaging in cell culture. As a result, these DV strains demon-
trate an augmented HS-binding phenotype (Anez et al., 2009;
ee et al., 2006b; Prestwood et al., 2008). This study utilized RSP
echnology as a new approach to investigate the use of HS as
 (co-)receptor for DV. RSPs have similar presentation of gpE to
hat of dengue virions, and we show that RSP interactions with
ero cells share similar key features of heparin and HS sensitiv-
ty as infectious DV (Fig. 3). Utilizing RSPs enables the direct study
f HS-interaction by biochemical methods (e.g., ELISA) as well as
ell-binding assays without concerns of inadvertently introduc-
ng adaptive mutations, which can and has reported to occur with
nfectious DV propagation (Anez et al., 2009; Lee et al., 2006b;
restwood et al., 2008). In this study, four strains of DV1 represent-
ng low- and high-passage histories were selected for production
f RSPs with their native, codon-optimized prM–gpE sequences.
estern blot, EM, MALDI-MS, and separation proﬁles from sucrose
radient ultracentrifugation were used to examine the identity and
ntegrity of the RSPs. Taken together, the results demonstrated the
SPs to be intact with similar physicochemical features as shown
n previous studies (Allison et al., 2003; Wang et al., 2009).
Interaction between HS and DV has been demonstrated in
revious studies by multiple assays, including ELISA and chro-
atography with immobilized heparin (Chen et al., 1997; Kato
t al., 2010; Lee et al., 2006b; Marks et al., 2001; Pattnaik et al.,
007; Watterson et al., 2012), as well as changes in infectivity
fter treatment of cells with heparinases (Germi et al., 2002; Hil-
ard and Stockert, 2000; Martinez-Barragan and del Angel, 2001;
kamoto et al., 2011; Prestwood et al., 2008; Thaisomboonsuk et al.,
005; Thepparit et al., 2004) or presence of competing soluble hep-
rin/HS (Chen et al., 1997; Germi et al., 2002; Hilgard and Stockert,
000; Kato et al., 2010; Lee et al., 2006b; Lin et al., 2002; Okamoto
t al., 2011; Thaisomboonsuk et al., 2005). We  ﬁrst studied HS–RSP
nteraction by use of a heparin ELISA, the results of which showed
inding of all four strains of DV1 RSPs to immobilized heparin. The
peciﬁcity of binding was demonstrated by competition with solu-
le heparin and HS. To conﬁrm and extend these ﬁndings, in vitro
ell-based studies were carried out. Soluble heparin and HS were
ound to potently inhibit of all four strains of RSPs to Vero cellsEM/F12 medium containing heparin, heparan sulfate or PBS as a negative control.
s and incubated for 4 h at 37 ◦C to allow RSP binding to cells. Cells were then ﬁxed
tion.
as well as that of infectious DV strain TH-Sman. Collectively, these
results are broadly consistent with previous studies showing inter-
action between DV and HS, and they extend the characterization
DV–HS interactions by demonstrating the use of HS by clinically
relevant strains.
Although all RSPs bound to heparin in ELISA studies, the inten-
sity of binding across RSP concentrations varied for each strain.
RSPs of L-BR and L-ThD1, strains which have low-passage his-
tories, showed signiﬁcant binding to heparin and the overall
binding intensity appeared higher than that of RSPs of high passage
strains. Our ELISA binding results, which showed greater interac-
tion between heparin and the two  RSPs of low-passage strains, was
further supported by GAG competition results (Table 1). Competi-
tion studies demonstrated that, compared to high-passage strain
RSPs, low-passage strain RSPs had relatively higher IC50 values
for heparin and HS competition, indicating that these RSPs bound
tighter to immobilized heparin. The pattern of greater interaction
between RSPs and Vero cell was similarly shown by binding inhibi-
tion with competing heparin and HS (Fig. 4). These results support
the conclusion that both low-passage and high-passage strains of
DV1 utilize HS as an attachment factor.
Glycan speciﬁcity was investigated by the use of different GAGs
as competitors to RSP binding to adsorbed heparin. Our results
(Table 1) indicate that both primary sequence of the glycans as
well as the extent of sulfation affect binding. Heparin and HS,
which have similar backbone structures but different sulfation lev-
els, speciﬁcally competed RSP binding to immobilized heparin and
also partially inhibited RSP binding to Vero cells (Figs. 3 and 4).
While other studies have found HS as necessary for DV binding and
infection (Germi et al., 2002; Hilgard and Stockert, 2000; Martinez-
Barragan and del Angel, 2001; Okamoto et al., 2011; Prestwood
et al., 2008; Thaisomboonsuk et al., 2005; Thepparit et al., 2004),
a few studies have shown that heparin and highly sulfated HS, but
not unmodiﬁed HS, are able to bind DV/gpE and/or inhibit infec-
tion (Chen et al., 1997; Marks et al., 2001; Okamoto et al., 2011).
Different strains and even different serotypes as well as different
assay formats were used than with our study, which may  lead to
different observations.
Previous studies have shown that when propagated under cer-
tain cell culture conditions, multiple ﬂaviviruses including DV2 and
DV4 can undergo adaptive changes leading to an augmented HS-
binding phenotype (Anez et al., 2009; Lee et al., 2006b; Prestwood
et al., 2008). While multiple previous investigations of DV1, the sub-
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tilize HS as an attachment factor (Hilgard and Stockert, 2000; Kato
t al., 2010; Thepparit et al., 2004), three studies have indicated the
ontrary (Lin et al., 2002; Okamoto et al., 2011; Talarico et al., 2005).
n all cases, the strains used had either extensive passage histories
r such information was not provided, leaving it unclear whether
linical, low-passage DV1 strains utilize HS. Herein, we  have shown
SPs of both low- and high-passage strains of serotype 1 recognize
S and heparin. Apparent discrepant results observed between dif-
erent studies may  be explained by different assays and target cells
sed as well as strain-speciﬁc differences. Indeed, subtle to sub-
tantial strain-speciﬁc differences in HS-binding activities within a
erotype have been observed (Lin et al., 2002; Okamoto et al., 2011).
dditional viral and biochemical studies are needed to elucidate the
echanisms of HS usage by different strains and serotypes of DV.
In summary, we provide multiple lines of evidence supporting
n interaction between HS and clinically relevant DV1 strains. This
tudy was conducted using RSPs as a tool to capture properties
f gpE presentation as occurs on native dengue virions without
assaging of virus, which could lead to introduction of adap-
ive mutations. A number of HS-mimicking molecules have been
haracterized with anti-DV activity, namely fucoidan, carageenan,
l-galactan, and -d-glucans (Alen and Schols, 2012; Hidari et al.,
008; Pujol et al., 2002; Qiu et al., 2007; Talarico and Damonte,
007). PI-88, in particular, has been shown to increase survival in a
ouse model of DV infection (Lee et al., 2006a). Without strong
vidence that clinically relevant DV strains, in addition to lab-
dapted strains, recognize HS, it remains unknown whether HS
nalogs would be effective in clinical settings. Our study directly
emonstrates HS binding by both clinical and highly passaged
trains of DV, and as such, further substantiates efforts to develop
S-mimicking molecules as potential antiviral agents for clinical
reatment of dengue. Our results also provide evidence that dengue
SPs are similar to infectious dengue virions in their ability to rec-
gnize HS, a ﬁnding which supports the potential development
f RSPs, having similar antigenic properties as dengue virions, as
 safe and effective vaccine strategy (Ohtaki et al., 2010; Zhang
t al., 2011). Taken together, the improved understanding of the
olecular events of the DV infection process, including recogni-
ion of receptors, should aid the development of more speciﬁc and
ffective agents for combating dengue.
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